|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,406.50 DKK | +3.34% |
|
+3.15% | -5.76% |
| 04:50pm | Genmab A/S Announces Sales Results of Darzalex for Second Quarter of 2025 | CI |
| 04:38pm | Genmab says net sales of Darzalex in Q2 $3,539 mln | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 1.3TCr | ||||||
| 3.42TCr | ||||||
| 3.19TCr | ||||||
| 2.72TCr | - | |||||
| 1.95TCr | - | |||||
| 1.81TCr | - | - | - | - | - |
- Stock Market
- Equities
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition